Trials / Completed
CompletedNCT03899259
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 606 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2019-07-08
- Primary completion
- 2021-01-24
- Completion
- 2024-11-19
- First posted
- 2019-04-02
- Last updated
- 2026-04-07
- Results posted
- 2024-05-14
Locations
96 sites across 10 countries: United States, Argentina, Australia, Brazil, China, Israel, Japan, Puerto Rico, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03899259. Inclusion in this directory is not an endorsement.